ID   HCC1588
AC   CVCL_A351
SY   HCC-1588; Hamon Cancer Center 1588
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473071
DR   BioSample; SAMN10987742
DR   cancercelllines; CVCL_A351
DR   Cell_Model_Passport; SIDM01820
DR   Cosmic; 903638
DR   DepMap; ACH-001078
DR   GEO; GSM1374503
DR   IARC_TP53; 11451
DR   KCLB; 71588
DR   LiGeA; CCLE_148
DR   PharmacoDB; HCC1588_451_2019
DR   Wikidata; Q54881590
RX   PubMed=10353731;
RX   PubMed=24002593;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=29681454;
RX   PubMed=31068700;
RX   PubMed=31803961;
WW   http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: African American.
CC   HLA typing: A*32:01,32:01; B*51:01,51:01; C*01:02,01:02; DRB1*11:101,13:07 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.886_910del25; Zygosity=Unspecified (PubMed=10353731).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 10,11 (PubMed=25877200)
ST   D13S317: 11 (KCLB)
ST   D16S539: 10
ST   D18S51: 15,20
ST   D21S11: 27,28
ST   D3S1358: 17
ST   D5S818: 8
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 22
ST   Penta D: 12
ST   Penta E: 7,13
ST   TH01: 7,9
ST   TPOX: 8,12
ST   vWA: 16,19
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=10353731;
RA   Wistuba I.I., Bryant D., Behrens C., Milchgrub S., Virmani A.K.,
RA   Ashfaq R., Minna J.D., Gazdar A.F.;
RT   "Comparison of features of human lung cancer cell lines and their
RT   corresponding tumors.";
RL   Clin. Cancer Res. 5:991-1000(1999).
//
RX   PubMed=24002593; DOI=10.1038/bjc.2013.452;
RA   Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.;
RT   "Gene-expression data integration to squamous cell lung cancer
RT   subtypes reveals drug sensitivity.";
RL   Br. J. Cancer 109:1599-1608(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//